Tags

Type your tag names separated by a space and hit enter

Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon.
Biomed Res Int. 2020; 2020:9631731.BR

Abstract

Hepatotoxicity is historically the 3rd most common reason for drug withdrawal and toxicity-related discontinuation of treatment. This study was aimed at determining the incidence and the onset of hepatotoxicity and at evaluating the relationship of some risk factors for hepatotoxicity among Human Immunodeficiency Virus- (HIV-) positive, tuberculosis (TB), and HIV/TB patients on treatment. This was a prospective follow-up study involving 125 participants from the HIV/AIDS and TB treatment centres in three hospitals in Fako Division of Cameroon. These TB and HIV patients were initiated on RHEZ (R = Rifampicin, H = Isoniazid, E = Ethambutol, and P = Pyrazinamide) and TELE (efavirenz/tenofovir/lamivudine), respectively, and followed up for 12 weeks between September 2018 and November 2019. The levels of liver enzymes (transaminases, gamma-glutamyltransferase, alkaline phosphatase, and unconjugated/total bilirubin) were measured spectrophotometrically using serum. The Chi-squared (χ 2) test was used to assess the association between risk factors and hepatotoxicity, while the Kaplan-Meier survival analysis with the log-rank test was used to determine the occurrence of hepatotoxicity in the different groups. We followed the general study population for a total person time of 6580 person-days, with an incidence rate and cumulative incidence of 8 cases per 1000 person-days (53/6580 person-days) and 42.4% (53/125), respectively (95% confidence interval), recorded after 12 weeks of follow-up of all the participants. The onset of hepatotoxicity in the total study population was statistically significant (χ 2 = 9.5334; p = 0.022979; CI = 95%), with the majority observed at week eight of follow-up. Also, the incidence rate and cumulative incidence of hepatotoxicity with respect to HIV/AIDS, TB, and HIV/TB patients, respectively, at 95% confidence interval were: 8 cases per 1000 person-days (32/3843 person-days) and 32/76 (42.1%), 6 cases per 1000 person-days (12/1932 person-days) and 12/32 (37.5%), and 11 cases per 1000 person-days (9/805 person-days) and 9/17 (52.9%). This study shows that the incidence rate and cumulative incidence of hepatotoxicity in HIV/AIDS, TB, and HIV/TB patients on treatment were high in Fako Division, Cameroon. Also, it is very important to check these patients' liver function especially within the first 12 weeks of treatment.

Authors+Show Affiliations

Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon. Infectious Disease Laboratory, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon. Laboratory of Endocrinology and Radio-Elements, Medical Research Centre, Institute of Medical Research and Medicinal Plants Studies, P.O. Box 13033 Yaoundé, Cameroon. Central Africa Network on Tuberculosis, HIV/AIDS and Malaria-European and Developing Countries Clinical Trials Partnership (CANTAM-EDCTP), Congo.Infectious Disease Laboratory, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon. Central Africa Network on Tuberculosis, HIV/AIDS and Malaria-European and Developing Countries Clinical Trials Partnership (CANTAM-EDCTP), Congo. Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, P.O. Box 63, Buea, Cameroon.Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, P.O. Box 63, Buea, Cameroon.Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon. Infectious Disease Laboratory, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon. Medical Research and Bacteriology Laboratory, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon.Infectious Disease Laboratory, Faculty of Health Sciences, University of Buea, P.O. Box 63, Buea, Cameroon. Central Africa Network on Tuberculosis, HIV/AIDS and Malaria-European and Developing Countries Clinical Trials Partnership (CANTAM-EDCTP), Congo. Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, P.O. Box 63, Buea, Cameroon.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32462039

Citation

Enoh, Jude Eteneneng, et al. "Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients On Treatment in Fako Division, Southwest Region of Cameroon." BioMed Research International, vol. 2020, 2020, p. 9631731.
Enoh JE, Cho FN, Manfo FP, et al. Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon. Biomed Res Int. 2020;2020:9631731.
Enoh, J. E., Cho, F. N., Manfo, F. P., Ako, S. E., & Akum, E. A. (2020). Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon. BioMed Research International, 2020, 9631731. https://doi.org/10.1155/2020/9631731
Enoh JE, et al. Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients On Treatment in Fako Division, Southwest Region of Cameroon. Biomed Res Int. 2020;2020:9631731. PubMed PMID: 32462039.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon. AU - Enoh,Jude Eteneneng, AU - Cho,Frederick Nchang, AU - Manfo,Faustin Pascal, AU - Ako,Simon Eyongabane, AU - Akum,Eric Achidi, Y1 - 2020/05/12/ PY - 2020/01/16/received PY - 2020/04/04/revised PY - 2020/04/29/accepted PY - 2020/5/29/entrez PY - 2020/5/29/pubmed PY - 2020/5/29/medline SP - 9631731 EP - 9631731 JF - BioMed research international JO - Biomed Res Int VL - 2020 N2 - Hepatotoxicity is historically the 3rd most common reason for drug withdrawal and toxicity-related discontinuation of treatment. This study was aimed at determining the incidence and the onset of hepatotoxicity and at evaluating the relationship of some risk factors for hepatotoxicity among Human Immunodeficiency Virus- (HIV-) positive, tuberculosis (TB), and HIV/TB patients on treatment. This was a prospective follow-up study involving 125 participants from the HIV/AIDS and TB treatment centres in three hospitals in Fako Division of Cameroon. These TB and HIV patients were initiated on RHEZ (R = Rifampicin, H = Isoniazid, E = Ethambutol, and P = Pyrazinamide) and TELE (efavirenz/tenofovir/lamivudine), respectively, and followed up for 12 weeks between September 2018 and November 2019. The levels of liver enzymes (transaminases, gamma-glutamyltransferase, alkaline phosphatase, and unconjugated/total bilirubin) were measured spectrophotometrically using serum. The Chi-squared (χ 2) test was used to assess the association between risk factors and hepatotoxicity, while the Kaplan-Meier survival analysis with the log-rank test was used to determine the occurrence of hepatotoxicity in the different groups. We followed the general study population for a total person time of 6580 person-days, with an incidence rate and cumulative incidence of 8 cases per 1000 person-days (53/6580 person-days) and 42.4% (53/125), respectively (95% confidence interval), recorded after 12 weeks of follow-up of all the participants. The onset of hepatotoxicity in the total study population was statistically significant (χ 2 = 9.5334; p = 0.022979; CI = 95%), with the majority observed at week eight of follow-up. Also, the incidence rate and cumulative incidence of hepatotoxicity with respect to HIV/AIDS, TB, and HIV/TB patients, respectively, at 95% confidence interval were: 8 cases per 1000 person-days (32/3843 person-days) and 32/76 (42.1%), 6 cases per 1000 person-days (12/1932 person-days) and 12/32 (37.5%), and 11 cases per 1000 person-days (9/805 person-days) and 9/17 (52.9%). This study shows that the incidence rate and cumulative incidence of hepatotoxicity in HIV/AIDS, TB, and HIV/TB patients on treatment were high in Fako Division, Cameroon. Also, it is very important to check these patients' liver function especially within the first 12 weeks of treatment. SN - 2314-6141 UR - https://www.unboundmedicine.com/medline/citation/32462039/Abnormal_Levels_of_Liver_Enzymes_and_Hepatotoxicity_in_HIV-Positive,_TB,_and_HIV/TB-Coinfected_Patients_on_Treatment_in_Fako_Division,_Southwest_Region_of_Cameroon L2 - https://doi.org/10.1155/2020/9631731 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.